Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 21,371

Document Document Title
WO/2021/068950A1
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...  
WO/2021/070963A1
The present invention provides a compound for further improving the performance of an organic EL element, an organic electroluminescent element in which element performance is further improved, and an electronic device that includes such...  
WO/2021/070964A1
Provided are: a compound which further improves the performance of organic EL elements; an organic electroluminescent element which has performance that is further improved; and an electronic device which includes such an organic electro...  
WO/2021/070965A1
Provided are a compound that further improves the performance of organic EL elements, an organic electroluminescent element having further improved element performance, and an electronic device including such an organic electroluminescen...  
WO/2021/069184A1
The present invention relates to a compound of formula (I), to the use thereof in electronic devices, to methods for producing said compound, and to electronic devices containing the compound.  
WO/2021/065350A1
Provided are: a radiation-sensitive resin composition having excellent performance in terms of sensitivity, LWR, etc., in an exposure step even when a next-generation exposure technique is applied; and a method for forming a resist patte...  
WO/2021/065893A1
The purpose of the present invention is to provide a novel low-molecular-weight compound that exhibits agonistic activity on an orexin receptor and is expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the li...  
WO/2021/063347A1
Provided are a new impurity compound of rotigotine behenate, and the rotigotine behenate or a preparation thereof containing less than 0.5% by weight of the impurity compound, and an application of the impurity compound as a reference su...  
WO/2021/060277A1
Provided are, inter alia, compounds useful as aminating agents capable of introducing an amino group protected by a deprotectable protecting group into a wide range of substates under relatively moderate conditions, an aminating agent ha...  
WO/2021/060723A1
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an ele...  
WO/2021/056105A1
Compositions and methods based on the use of mutated HIV-1 gp120 polypeptides having amino acid substitutions at positions 61, 105, 108, 375, 474, 475 and 476 are described. These mutated HIV-1 gp120 polypeptides, which make the HIV env ...  
WO/2021/059017A1
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...  
WO/2021/060239A1
A compound represented by formula (1) below (wherein the various symbols in the formula are as defined in the description) provides an organic electroluminescent element having improved element performance.  
WO/2021/055849A1
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...  
WO/2021/051231A1
Disclosed is a new class of photo-responsive coordination compounds with at least one photochromic unit on a coordinating ligand. The photo-responsive coordination compounds are shown to be capable of acting as electroactive materials fo...  
WO/2021/054714A1
The present application provides: a heterocyclic compound capable of significantly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; and an organic light-emitting de...  
WO/2021/054804A1
The present invention pertains to a pharmaceutical or food composition for preventing or treating proteopathies, the pharmaceutical or food composition containing a novel p62 ligand compound represented by chemical formula 1, or a stereo...  
WO/2021/049654A1
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), a first light emitting layer (51) and a second light emitting layer (52) that is arranged between the first light emitting laye...  
WO/2021/049662A1
This organic electroluminescence element (1) includes a positive electrode (3), a negative electrode (4), a first light emitting layer (51), and a second light emitting layer (52) disposed between the first light emitting layer (51) and ...  
WO/2021/049663A1
An organic electroluminescence element (1) that has a positive electrode (3), a negative electrode (4), a first light-emitting layer (51), and a second light-emitting layer (52) that is arranged between the first light-emitting layer (51...  
WO/2021/050700A1
The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compoun...  
WO/2021/042410A1
Disclosed are a selective butyrylcholinesterase inhibitor having general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof. By testing the efficacy of treatment of Alzheimer's disea...  
WO/2021/045207A1
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...  
WO/2021/039654A1
The present invention provides: an active-ray-sensitive or radiation-sensitive resin composition having a solid material concentration of 10% by mass or more, the active-ray-sensitive or radiation-sensitive resin composition comprising a...  
WO/2021/039824A1
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...  
WO/2021/032933A1
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 an...  
WO/2020/013696A9
The present invention pertains to novel thiocycloheptyne derivatives of general formula (I) : and in particular to thiacycloalkynesulfoimine derivatives and their synthesis. The invention also relates to the use of the novel thiocyclohep...  
WO/2021/030091A1
The present disclosure relates to compounds, compositions and supplements that are capable of treating obesity. The disclosure further relates to methods of treating obesity in a subject in need thereof.  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/027567A1
Provided is a combination of an EP4 receptor antagonist and a PD-1 inhibitor for treating cancer. Specifically, provided is a product combination comprising: (i) a first pharmaceutical composition comprising (a) a first active ingredient...  
WO/2021/025593A1
Components of bioluminescent systems are widely used reagents for multiple analyses including diagnostic systems, quality control systems, drug trial systems and the like. The present group of inventions discloses components of the biolu...  
WO/2021/023143A1
Disclosed are a synthetic scheme for a Relugolix intermediate and Relugolix. The synthetic scheme efficiently avoids the use of a highly toxic substance, i.e. methyl chloroformate or ethyl chloroformate, and uses other kinds of chlorofor...  
WO/2021/025448A1
The present invention relates to a novel compound that enables formation of an additional hydrogen bond with a specific amino acid position in histone acetyltransferase (HAT) p300 through the structural analysis of the HAT p300. The nove...  
WO/2021/019558A1
The present invention discloses an efficient process for synthesis of photosensitizer, 5-(3-pyridyl)-2,2'-bithiophene in high yield and purity.  
WO/2021/019559A1
Disclosed herein is a novel simple, short process for synthesis of the photosensitizer, 5-(3-pyridyl)-2,2'-bithiophene.  
WO/2021/018105A1
Provided are substituted pyrimidinedione compounds and uses thereof, as well as pharmaceutical compositions containing such compounds, which can be used as gonadotropin releasing hormone receptor antagonists. Provided are a method for pr...  
WO/2021/012014A1
The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase e...  
WO/2021/012689A1
Disclosed herein are phenylthiophene sulfonamide compounds, pharmaceutical compositions, a preparation method therefor and use thereof. The compounds of the present invention are capable of effectively and selectively inhibiting Bcl-xL, ...  
WO/2021/016449A1
Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/ fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and t...  
WO/2021/015555A1
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device comprising the organic electric element.  
WO/2021/009566A1
Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (...  
WO/2021/007661A1
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...  
WO/2021/009567A1
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.  
WO/2021/001331A1
The present disclosure relates to substituted thiophene carboxamide derivatives of formula (I), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.  
WO/2020/263989A1
Compounds that inhibit JNK, e.g., JNK2 and/or JNK3, such as fused thiophenes, and methods of making and using the compounds are provided.  
WO/2020/259078A1
Provided is a method for preparing an adamantyl-containing triphenylamine derivative, the method comprising first reacting an aryl halogenated adamantane or an aryl adamantane ester with a primary aromatic amine without separation or pur...  
WO/2020/262648A1
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...  
WO/2020/262451A1
The invention addresses the problem that metal-organic frameworks have conventionally only been produced with terephthalic acids having a limited range of substituents even though the amount and type of gas stored thereby can vary depend...  
WO/2020/264176A1
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the...  
WO/2020/262507A1
Provided are a compound that further improves the performance of an organic EL element, an organic electroluminescence element having improved element performance, and an electronic device including such an organic electroluminescence el...  

Matches 1 - 50 out of 21,371